Are thermogenic proteins and adipokine chemerin affected by monoclonal antibody therapy in asthma?

Bulut T., Yalcin A. D., ÇELİK B., Genc G. E., GÖÇMEN A. Y., GÜMÜŞLÜ S.

EURASIAN JOURNAL OF PULMONOLOGY, cilt.21, sa.3, ss.161-166, 2019 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4103/ejop.ejop_60_18
  • Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.161-166
  • Anahtar Kelimeler: Asthma, CD16-56, CD80, chemerin, interleukin-1 beta, irisin, natural killer activity, omalizumab, ALLERGIC-ASTHMA, DISEASE, OMALIZUMAB, WEAKNESS, IRISIN, COPD
  • Akdeniz Üniversitesi Adresli: Evet

Özet

BACKGROUND: Irisin is a thermogenic protein that sources outgoing energy by converting white adipose tissue to brown adipose tissue. Chemerin is originally identified as a chemoattractant protein that mainly mediating the chemotaxis of dendritic cells and natural killer cells (NKCs). The aim of this study is to assess the potential impact of immune modulation-related chemerin and irisin concentrations together with cell surface markers (CSM) in allergic asthmatic patients under omalizumab treatment.